Impact of Different CRRT Modalities, Dosing Strategies, and Timing on Kidney Recovery and Prolonged Kidney Dysfunction

A Multicentric Observational Study Examining How Different CRRT Modalities, Dosing Strategies, and Timing Impact Kidney Recovery and the Development of Prolonged Kidney Dysfunction (Acute Kidney Disease) in Critically Ill Patients

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07052617

Acronym

KARMA

Enrollment

2500

Registered

2025-07-04

Start date

2025-09-25

Completion date

2026-12-25

Last updated

2025-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Disease, Acute Kidney Injury

Brief summary

KARMA study is a hospital-based research study looking at how different ways of delivering kidney support therapy (CRRT) affect patients who are critically ill. In some cases, the kidneys may temporarily stop working in very sick patients, and machines are used to filter the blood. This study is exploring whether the way the investigators use these machines - how early to start, how much treatment to give, and what type to choose - makes a difference in how well the kidneys recover. By learning from many hospitals and hundreds of patients, KARMA hopes to improve treatment choices and help patients regain their kidney function faster.

Interventions

DEVICEContinuos renal replacement therapy

Different modalities of CRRT: continuous veno-venous hemofiltration; continuous veno-venous hemodialysis and continuous veno-venous hemodiafiltration Different doses of CRRT: low effluent dose (\<15 ml/kg/h); medium-low effluent dose (15-25 ml/kg/h); standard effluent dose (25-30 ml/kg/h); high effluent dose (\>30 ml/kg/h

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acute kidney injury * ICU administration

Exclusion criteria

* Pre-existing CKD (GFR \< 30 ml/min/1,73m2) * Chronic dialysis-dependent end-stage renal failure

Design outcomes

Primary

Measure	Time frame	Description
Percentage of patients with AKD	90 days	Percentage of patients with AKD divided by subgroups regarding AKI etiology

Secondary

Measure	Time frame	Description
Durations and severity of AKD, free days of CRRT and kidney recovery	90 days	AKD duration in days AKD severity described and compared by AKI stages Patients with AKD divided by subgroups regarding indication for CRRT (fluid overload, electrolyte disturbances, metabolic acidosis, uremia, oliguria/anuria) and CRRT dose (ml/kg/hour) CRRT free days during ICU Kidney recovery/stage of CKD/dialysis dependency

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026